Abstract
eEF1A2 (eukaryotic protein elongation factor 1 alpha 2) is a protein translation factor that is likely a human oncogene by virtue of its capacity to transform mammalian cells and its high expression in tumors of the ovary, breast and lung. Here, we show that expression of eEF1A2 is sufficient to stimulate the formation of filopodia in BT549 human breast cancer cells and non-transformed Rat2 cells. Filopodia formation in eEF1A2-expressing cells is dependent on the activity of phosphatidylinositol-3 kinase (PI3K), and the ROCK and Akt kinases. Furthermore, eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent fashion and inactivation of eEF1A2 by short interfering RNA reduces Akt activity. Using breast cancer cell line BT 549, we show that eEF1A2 expression stimulates cell migration and invasion in a largely PI3K- and Akt-dependent manner. These results suggest that eEF1A2 regulates oncogenesis through Akt and PI3K-dependent cytoskeletal remodeling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams AT, Auersperg N . (1985). A cell line, ROSE 199, derived from normal rat ovarian surface epithelium. Exp Cell Biol 53: 181–188.
Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH et al. (2002). Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31: 301–305.
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R et al. (2003). Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63: 196–206.
Carpenter CL, Cantley LC . (1990). Phosphoinositide kinases. Biochemistry 29: 11147–11156.
Carragher NO, Frame MC . (2004). Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14: 241–249.
Chang R, Wang E . (2006). Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem, epub ahead of print.
Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M et al. (2004). Regulation of anoikis by Cdc42 and Rac1. Proc Natl Acad Sci USA 101: 14479–14484.
Chodniewicz D, Klemke RL . (2004). Guiding cell migration through directed extension and stabilization of pseudopodia. Exp Cell Res 301: 31–37.
Condeelis J . (1995). Elongation factor 1 alpha, translation and the cytoskeleton. Trends Biochem Sci 20: 169–170.
Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL . (1994). GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem 269: 15411–15414.
Edmonds BT, Wyckoff J, Yeung YG, Wang Y, Stanley ER, Jones J et al. (1996). Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci 109(Part 11): 2705–2714.
Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K et al. (2005). Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell 9: 389–402.
Fitzsimmons SA, Ireland H, Barr NI, Cuthbert AP, Going JJ, Newbold RF et al. (2003). Human squamous cell carcinomas lose a mortality gene from chromosome 6q14.3 to q15. Oncogene 22: 1737–1746.
Fruman DA, Meyers RE, Cantley LC . (1998). Phosphoinositide kinases. Annu Rev Biochem 67: 481–507.
Gross SR, Kinzy TG . (2005). Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12: 772–778.
Heilmeyer Jr LM, Vereb Jr G, Vereb G, Kakuk A, Szivak I . (2003). Mammalian phosphatidylinositol 4-kinases. IUBMB Life 55: 59–65.
Hershey JW . (1991). Translational control in mammalian cells. Annu Rev Biochem 60: 717–755.
Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K . (2004). Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 15: 321–329.
Kahns S, Lund A, Kristensen P, Knudsen CR, Clark BF, Cavallius J et al. (1998). The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. Nucleic Acids Res 26: 1884–1890.
Knudsen SM, Frydenberg J, Clark BF, Leffers H . (1993). Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem 215: 549–554.
Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, Wu TD et al. (2006). Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat (e-pub ahead of print).
Kumar R, Gururaj AE, Barnes CJ . (2006). p21-activated kinases in cancer. Nat Rev Cancer 6: 459–471.
Lau J, Castelli LA, Lin EC, Macaulay SL . (2006). Identification of elongation factor 1alpha as a potential associated binding partner for Akt2. Mol Cell Biochem 286: 17–22.
Lee JM . (2003). The role of protein elongation factor eEF1A2 in ovarian cancer. Reprod Biol Endocrinol 1: 69.
Lee S, Wolfraim LA, Wang E . (1993). Differential expression of S1 and elongation factor-1 alpha during rat development. J Biol Chem 268: 24453–24459.
Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL et al. (2005). Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 25: 2628–2635.
Meijer HJ, Munnik T . (2003). Phospholipid-based signaling in plants. Annu Rev Plant Biol 54: 265–306.
Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ et al. (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197–209.
Munshi R, Kandl KA, Carr-Schmid A, Whitacre JL, Adams AE, Kinzy TG . (2001). Overexpression of translation elongation factor 1A affects the organization and function of the actin cytoskeleton in yeast. Genetics 157: 1425–1436.
Nathrath MH, Kuosaite V, Rosemann M, Kremer M, Poremba C, Wakana S et al. (2002). Two novel tumor suppressor gene loci on chromosome 6q and 15q in human osteosarcoma identified through comparative study of allelic imbalances in mouse and man. Oncogene 21: 5975–5980.
Overduin M, Cheever ML, Kutateladze TG . (2001). Signaling with phosphoinositides: better than binary. Mol Interv 1: 150–159.
Owen CH, DeRosier DJ, Condeelis J . (1992). Actin crosslinking protein EF-1a of Dictyostelium discoideum has a unique bonding rule that allows square-packed bundles. J Struct Biol 109: 248–254.
Pencil SD, Toh Y, Nicolson GL . (1993). Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Res Treat 25: 165–174.
Pendaries C, Tronchere H, Arbibe L, Mounier J, Gozani O, Cantley L et al. (2006). PtdIns(5)P activates the host cell PI3-kinase/Akt pathway during Shigella flexneri infection. EMBO J 25: 1024–1034.
Qian Y, Corum L, Meng Q, Blenis J, Zheng JZ, Shi X et al. (2004). PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol 286: C153–C163.
Reinhard M, Halbrugge M, Scheer U, Wiegand C, Jockusch BM, Walter U . (1992). The 46/50 kDa phosphoprotein VASP purified from human platelets is a novel protein associated with actin filaments and focal contacts. EMBO J 11: 2063–2070.
Riento K, Ridley AJ . (2003). Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446–456.
Rodrigues SP, Fathers KE, Chan G, Zuo D, Halwani F, Meterissian S et al. (2005). CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells. Mol Cancer Res 3: 183–194.
Svitkina TM, Bulanova EA, Chaga OY, Vignjevic DM, Kojima S, Vasiliev JM et al. (2003). Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol 160: 409–421.
Thornton S, Anand N, Purcell D, Lee J . (2003). Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 81: 536–548.
Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR et al. (2005). Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 5: 113.
Tornieri K, Welshhans K, Geddis MS, Rehder V . (2006). Control of neurite outgrowth and growth cone motility by phosphatidylinositol-3-kinase. Cell Motil Cytoskeleton 63: 173–192.
Verhagen PC, Hermans KG, Brok MO, van Weerden WM, Tilanus MG, de Weger RA et al. (2002). Deletion of chromosomal region 6q14–16 in prostate cancer. Int J Cancer 102: 142–147.
Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.
Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S et al. (2004). Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Science 304: 1164–1166.
Yamaguchi H, Wyckoff J, Condeelis J . (2005). Cell migration in tumors. Curr Opin Cell Biol 17: 559–564.
Yang F, Demma M, Warren V, Dharmawardhane S, Condeelis J . (1990). Identification of an actin-binding protein from Dictyostelium as elongation factor 1. Nature 347: 494–496.
Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI et al. (2004). Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64: 4394–4399.
Yang W, Burkhart W, Cavallius J, Merrick WC, Boss WF . (1993). Purification and characterization of a phosphatidylinositol 4-kinase activator in carrot cells. J Biol Chem 268: 392–398.
Zhou GL, Zhuo Y, King CC, Fryer BH, Bokoch GM, Field J . (2003). Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. Mol Cell Biol 23: 8058–8069.
Acknowledgements
We thank Jessica Rousseau for technical assistance and Stephen Lee, Illona Skerjanc, Barbara Vanderhyden, Nadine Wiper-Bergeron and Zemin Yao for helpful discussions and critical reading of this article. This work was supported by funding from the Canadian Breast Cancer Research Alliance (CBCRA) and the National Cancer Institute of Canada (JML).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Amiri, A., Noei, F., Jeganathan, S. et al. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 26, 3027–3040 (2007). https://doi.org/10.1038/sj.onc.1210101
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210101
Keywords
This article is cited by
-
Oncogenic activation of EEF1A2 expression: a journey from a putative to an established oncogene
Cellular & Molecular Biology Letters (2024)
-
Discovery of a nitroaromatic nannocystin with potent in vivo anticancer activity against colorectal cancer by targeting AKT1
Acta Pharmacologica Sinica (2024)
-
A novel tumor suppressor encoded by a 1p36.3 lncRNA functions as a phosphoinositide-binding protein repressing AKT phosphorylation/activation and promoting autophagy
Cell Death & Differentiation (2023)
-
Overexpressing eukaryotic elongation factor 1 alpha (eEF1A) proteins to promote corticospinal axon repair after injury
Cell Death Discovery (2022)
-
Identification of loci associated with susceptibility to bovine paratuberculosis and with the dysregulation of the MECOM, eEF1A2, and U1 spliceosomal RNA expression
Scientific Reports (2021)